NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The global radiopharmaceuticals market size is estimated to increase by USD 4.37 billion from 2021 to 2026. Moreover, the market's growth momentum will accelerate at a CAGR of 9.9%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Discover more insights on market size before buying the full report -Request a sample report
Radiopharmaceuticals market – Vendor analysis
Vendor offerings -
- Bayer AG - The company offers radiopharmaceuticals such as Targeted Thorium-Conjugate (TTC).
- Cardinal Health Inc. - The company offers radiopharmaceuticals such as Azedra- Iodine I 131 iobenguane.
- Curium - The company offers products such as the Octreoscan- kit for the preparation of indium In 111 pentetreotide.
- Eckert and Ziegler AG - The company offers radiopharmaceuticals such as GalliaPharm Ge-68/Ga-68 generator.
- For details on vendors and their offerings – Buy the report!
Vendor landscape –
The global radiopharmaceuticals market is fragmented, with the presence of several global as well as regional vendors. A few prominent vendors that offer radiopharmaceuticals in the market are Actinium Pharmaceuticals Inc., Bayer AG, Bracco Spa, BWX Technologies Inc., Cardinal Health Inc., Curium, Eckert and Ziegler AG, Eczacibasi Holding AS, Fusion Pharmaceuticals Inc., General Electric Co., Jubilant Pharmova Ltd., Lantheus Holdings Inc., Navidea Biopharmaceuticals Inc., NorthStar Medical Radioisotopes LLC, Novartis AG, Radiomedix Inc., Siemens Healthineers AG, Sinotau Pharmaceuticals, Telix Pharmaceuticals Ltd., and The South African Nuclear Energy Corp. SOC Ltd. and others.
The global radiopharmaceuticals market is highly competitive. Vendors offer a broad range of products and have substantial financial, manufacturing, sales, marketing, and distribution resources. They make significant investments in R&D and have a strong geographical reach. Small and medium-sized vendors are focusing on expanding their businesses internationally. The competitive environment in the market is expected to intensify during the forecast period due to technological advances, a growing number of new product approvals, an increasing number of M&A and strategic collaborations, and the growing focus of vendors on expanding their reach.
Radiopharmaceuticals market - Customer landscape
To help companies evaluate and develop growth strategies, the report outlines –
- Key purchase criteria
- Adoption rates
- Adoption lifecycle
- Drivers of price sensitivity
Radiopharmaceuticals market - Segmentation assessment
Segment overview
Technavio has segmented the market based on application (diagnostics and therapeutics).
- The diagnostics segment will account for a significant share of the market's growth during the forecast period. Radiopharmaceuticals are taken orally or intravenously. External detectors such as gamma cameras capture radiations from radiopharmaceuticals and form images. The process of producing an image is known as scintigraphy. Technetium-99m is the most common radioisotope used in diagnostic nuclear medicine and is used for the diagnosis of several types of cancers. Such applications will drive the growth of this segment during the forecast period.
Geography overview
Based on geography, the global radiopharmaceuticals market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global radiopharmaceuticals market.
- North America will account for 44% of the market's growth during the forecast period. The US and Canada are the key contributors to the radiopharmaceuticals market in the region. However, market growth in North America will be slower than the growth of the market in Asia. Rising investments in R&D activities in the healthcare industry, especially in the US, will drive the growth of the radiopharmaceuticals market in North America during the forecast period.
Radiopharmaceuticals market – Market dynamics
Leading drivers - The rising burden of neurological disorders is driving the radiopharmaceuticals market growth. Radiopharmaceuticals have advantages such as high efficacy and non-invasive external monitoring. Imaging instruments such as SPECT and PET use radiopharmaceuticals to diagnose brain disorders. Therefore, radiopharmaceuticals play a significant role in the treatment and diagnostics of neurological disorders. The rising incidence of neurological disorders will increase the demand for radiopharmaceutical drugs, which, in turn, is fueling the market growth.
Key trends - Partnerships for the development of radiopharmaceuticals are supporting the radiopharmaceuticals market growth. Leading companies are forming partnerships to address concerns related to medical imaging. For instance, in May 2014, as part of a strategic partnership, SHINE Medical will supply Mo-99 to GE Healthcare. This radioisotope gets converted to Tc-99 after decay and is used in medical imaging. Such partnerships are expected to support market growth during the forecast period.
Major challenges – Preparation and dispensing problems associated with radiopharmaceuticals are challenging the radiopharmaceuticals market growth. The chemical reactions involved in the preparation of radiopharmaceuticals may generate radiochemical impurities. The radiation can also lead to radiolytic effects. Moreover, the chemical properties of radiopharmaceuticals may lead to undesired adsorption to the components of the container. These issues may pose a challenge to the growth of the market during the forecast period.
What are the key data covered in this radiopharmaceuticals market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the radiopharmaceuticals market between 2022 and 2026
- Precise estimation of the size of the radiopharmaceuticals market and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the radiopharmaceuticals market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of Radiopharmaceuticals Market vendors
Gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Related Reports:
The anesthesia drugs market is estimated to grow at a CAGR of 4.35% between 2022 and 2027. The size of the market is forecasted to increase by USD 1,383.65 million. This report extensively covers market segmentation by type (general anesthesia, local, and regional anesthesia), route of administration (intravenous, inhalational, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The autoimmune drugs market is estimated to grow at a CAGR of 6.39% between 2022 and 2027. The size of the market is forecasted to increase by USD 29,314.5 million. This report extensively covers market segmentation by therapy area (rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, and others), distribution channel (hospital, pharmacy, drug store/retail pharmacy, and online), and geography (North America, Europe, Asia, and Rest of World (ROW).
Radiopharmaceuticals Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.9% |
Market growth 2022-2026 |
USD 4.37 billion |
Market structure |
Fragmented |
YoY growth 2021-2022 (%) |
9.0 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading vendors, market positioning of vendors, competitive strategies, and industry risks |
Key companies profiled |
Actinium Pharmaceuticals Inc., Bayer AG, Bracco Spa, BWX Technologies Inc., Cardinal Health Inc., Curium, Eckert and Ziegler AG, Eczacibasi Holding AS, Fusion Pharmaceuticals Inc., General Electric Co., Jubilant Pharmova Ltd., Lantheus Holdings Inc., Navidea Biopharmaceuticals Inc., NorthStar Medical Radioisotopes LLC, Novartis AG, Radiomedix Inc., Siemens Healthineers AG, Sinotau Pharmaceuticals, Telix Pharmaceuticals Ltd., and The South African Nuclear Energy Corp. SOC Ltd. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio's health care market reports
Table of contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Application
- 5.1 Market segments
- Exhibit 24: Chart on Application - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Application - Market share 2021-2026 (%)
- 5.2 Comparison by Application
- Exhibit 26: Chart on Comparison by Application
- Exhibit 27: Data Table on Comparison by Application
- 5.3 Diagnostics - Market size and forecast 2021-2026
- Exhibit 28: Chart on Diagnostics - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Diagnostics - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Diagnostics - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Diagnostics - Year-over-year growth 2021-2026 (%)
- 5.4 Therapeutics - Market size and forecast 2021-2026
- Exhibit 32: Chart on Therapeutics - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Therapeutics - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Therapeutics - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Therapeutics - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Application
- Exhibit 36: Market opportunity by Application ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 China - Market size and forecast 2021-2026
- Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Bayer AG
- Exhibit 85: Bayer AG - Overview
- Exhibit 86: Bayer AG - Business segments
- Exhibit 87: Bayer AG - Key news
- Exhibit 88: Bayer AG - Key offerings
- Exhibit 89: Bayer AG - Segment focus
- 10.4 Cardinal Health Inc.
- Exhibit 90: Cardinal Health Inc. - Overview
- Exhibit 91: Cardinal Health Inc. - Business segments
- Exhibit 92: Cardinal Health Inc. - Key news
- Exhibit 93: Cardinal Health Inc. - Key offerings
- Exhibit 94: Cardinal Health Inc. - Segment focus
- 10.5 Curium
- Exhibit 95: Curium - Overview
- Exhibit 96: Curium - Product / Service
- Exhibit 97: Curium - Key offerings
- 10.6 Eckert and Ziegler AG
- Exhibit 98: Eckert and Ziegler AG - Overview
- Exhibit 99: Eckert and Ziegler AG - Business segments
- Exhibit 100: Eckert and Ziegler AG - Key news
- Exhibit 101: Eckert and Ziegler AG - Key offerings
- Exhibit 102: Eckert and Ziegler AG - Segment focus
- 10.7 Eczacibasi Holding AS
- Exhibit 103: Eczacibasi Holding AS - Overview
- Exhibit 104: Eczacibasi Holding AS - Product / Service
- Exhibit 105: Eczacibasi Holding AS - Key offerings
- 10.8 General Electric Co.
- Exhibit 106: General Electric Co. - Overview
- Exhibit 107: General Electric Co. - Business segments
- Exhibit 108: General Electric Co. - Key news
- Exhibit 109: General Electric Co. - Key offerings
- Exhibit 110: General Electric Co. - Segment focus
- 10.9 Jubilant Pharmova Ltd.
- Exhibit 111: Jubilant Pharmova Ltd. - Overview
- Exhibit 112: Jubilant Pharmova Ltd. - Business segments
- Exhibit 113: Jubilant Pharmova Ltd. - Key news
- Exhibit 114: Jubilant Pharmova Ltd. - Key offerings
- Exhibit 115: Jubilant Pharmova Ltd. - Segment focus
- 10.10 Lantheus Holdings Inc.
- Exhibit 116: Lantheus Holdings Inc. - Overview
- Exhibit 117: Lantheus Holdings Inc. - Business segments
- Exhibit 118: Lantheus Holdings Inc. - Key offerings
- Exhibit 119: Lantheus Holdings Inc. - Segment focus
- 10.11 Novartis AG
- Exhibit 120: Novartis AG - Overview
- Exhibit 121: Novartis AG - Business segments
- Exhibit 122: Novartis AG - Key offerings
- Exhibit 123: Novartis AG - Segment focus
- 10.12 Siemens Healthineers AG
- Exhibit 124: Siemens Healthineers AG - Overview
- Exhibit 125: Siemens Healthineers AG - Business segments
- Exhibit 126: Siemens Healthineers AG - Key news
- Exhibit 127: Siemens Healthineers AG - Key offerings
- Exhibit 128: Siemens Healthineers AG - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 129: Inclusions checklist
- Exhibit 130: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 131: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 132: Research methodology
- Exhibit 133: Validation techniques employed for market sizing
- Exhibit 134: Information sources
- 11.5 List of abbreviations
- Exhibit 135: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article